Bourantas K L, Georgiou I, Seferiadis K
Department of Internal Medicine, University of Ioannina Medical School, Greece.
Acta Haematol. 1994;92(2):79-82. doi: 10.1159/000204179.
Six sickle cell/beta-thalassemia patients (3 males and 3 females) were treated with 500 U/kg body weight human recombinant erythropoietin (h-rEPO) along with 300 mg/day iron sulfate in two phases, for a period of 90 days. Fetal hemoglobin (HbF) was assayed every 2 weeks and the gamma-chain ratio at three successive intervals during the treatment. All patients showed a moderate to high increase in their HbF values (1.25- to 12-fold). The gamma-chain ratio, as determined by high performance liquid chromatography was found to be unaffected by the HbF increase. Two patients with the newborn gamma-chain ratio, responded faster to the h-rEPO treatment and achieved higher HbF values than the rest of the group. The h-rEPO treatment was very well tolerated and had a positive effect on the general clinical condition of all the patients.
六名镰状细胞/β地中海贫血患者（3名男性和3名女性）分两个阶段接受了500 U/kg体重的人重组促红细胞生成素（h-rEPO）治疗，并同时每天服用300毫克硫酸亚铁，为期90天。每2周检测一次胎儿血红蛋白（HbF），并在治疗期间连续三个时间段检测γ链比例。所有患者的HbF值均有中度到高度升高（1.25至12倍）。通过高效液相色谱法测定的γ链比例不受HbF升高的影响。两名具有新生儿γ链比例的患者对h-rEPO治疗反应更快，HbF值高于组内其他患者。h-rEPO治疗耐受性良好，对所有患者的总体临床状况有积极影响。
